Antibiotic exposure during immunotherapy for liver cancer was linked to shorter survival

Design

Systematic review and meta-analysis of 12 retrospective cohorts

Population

3,643 patients with HCC treated with checkpoint inhibitors

Primary outcome

Overall and progression-free survival

Effect

OS HR 1.29 (95% CI 1.17–1.41); PFS HR 1.27 (1.01–1.59), not robust

A meta-analysis of 12 retrospective cohorts (3,643 patients with hepatocellular carcinoma on checkpoint inhibitors, 761 exposed to antibiotics) compared outcomes by antibiotic use.

Antibiotic exposure was associated with shorter overall survival (median 12.2 vs 17.0 months; HR 1.29, 95% CI 1.17–1.41), a finding robust in sensitivity analyses. The association with progression-free survival (HR 1.27) was not robust, and response rates did not differ.

The proposed mechanism is disruption of the gut microbiome that supports immunotherapy response. But patients who need antibiotics are often sicker, so confounding is likely. The practical message is stewardship, not withholding antibiotics from patients with infection.

• Avoid unnecessary antibiotics in patients on checkpoint inhibitors
• Treat genuine infections fully — the association may reflect illness severity
• Prefer the narrowest effective antibiotic and shortest course
• Record antibiotic exposure when interpreting immunotherapy response

Why it matters

A routine prescription may carry a cost in patients whose response depends on the microbiome.

Don't overread it

These are retrospective associations; sicker patients are more likely to receive antibiotics.

The statistics, in plain English

A hazard ratio of 1.29 means about 29% higher risk of death at any point among those given antibiotics, without showing that antibiotics caused it.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.